tiprankstipranks
Arvinas price target lowered to $81 from $87 at H.C. Wainwright
PremiumThe FlyArvinas price target lowered to $81 from $87 at H.C. Wainwright
9d ago
Arvinas Holding Company Receives ‘Buy’ Rating: Promising Clinical Advances and Strategic Pipeline Developments
Premium
Ratings
Arvinas Holding Company Receives ‘Buy’ Rating: Promising Clinical Advances and Strategic Pipeline Developments
9d ago
Arvinas Reports 2024 Financial Results and Pipeline Progress
Premium
Company Announcements
Arvinas Reports 2024 Financial Results and Pipeline Progress
10d ago
ARVN Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsARVN Upcoming Earnings Report: What to Expect?
12d ago
Arvinas Holding: Buy Rating Anticipates Major Upside from VERITAC-2 and PROTACs
Premium
Ratings
Arvinas Holding: Buy Rating Anticipates Major Upside from VERITAC-2 and PROTACs
18d ago
Arvinas price target lowered to $32 from $48 at Barclays
Premium
The Fly
Arvinas price target lowered to $32 from $48 at Barclays
18d ago
Arvinas updates milestones for 2025
PremiumThe FlyArvinas updates milestones for 2025
1M ago
Arvinas down on investors’ read of Lilly data, says BTIG
Premium
The Fly
Arvinas down on investors’ read of Lilly data, says BTIG
2M ago
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Premium
The Fly
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100